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Background: Albuminuria marks renal disease and cardiovascular risk. It was estimated to contribute 75% of the
risk of all-cause natural death in one Aboriginal group. The urine albumin/creatinine ratio (ACR) is commonly used
as an index of albuminuria. This study aims to examine the associations between demographic factors,
anthropometric index, blood pressure, lipid-protein measurements and other biomarkers and albuminuria in a
cross-sectional study in a high-risk Australian Aboriginal population. The models will be evaluated for albuminuria at
or above the microalbuminuria threshold, and at or above the “overt albuminuria” threshold with the potential to
distinguish associations they have in common and those that differ.
Methods: This was a cross-sectional study of 598 adults aged 18–76 years. All participants were grouped into
quartiles by age. Logistic regression models were used to explore the correlates of ACR categories.
Results: The significant correlates were systolic blood pressure (SBP), C-reactive protein (CRP), uric acid, diabetes,
gamma-glutamyl transferase (GGT) (marginally significant, p = 0.054) and serum albumin (negative association)
for ACR 17+ (mg/g) for men and 25+ for women. Independent correlates were SBP, uric acid, diabetes, total
cholesterol, alanine amino transferase (ALT), Cystatin C and serum albumin (negative association) for overt
albuminuria; and SBP, CRP and serum albumin only for microalbuminuria.
Conclusions: This is the most detailed modelling of pathologic albuminuria in this setting to date. The somewhat
variable association with risk factors suggests that microalbuminuria and overt albuminuria might reflect different as
well as shared phenomena.
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Australian Aboriginal people, especially those living in
remote areas, have greater rates of all-cause mortality,
cardiovascular death and end-stage renal disease (ESRD)
[1-3] compared with other Australian ethnicities. The in-
cidence of patients with ESRD starting renal replace-
ment therapy in remote regions is up to 30 times the
national incidence for all Australians [4]. The urine albu-
min/creatinine ratio (ACR) is commonly used as an
index of albuminuria. In a study of one high-risk com-
munity, albuminuria, which was pervasive, and much
more common than hypertension and diabetes and, not* Correspondence: w.hoy@uq.edu.au
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reproduction in any medium, provided the oronly marked all future risk of renal failure, the treatment
of which is very costly, but also predicted cardiovascular
and nonrenal noncardiovascular deaths [2,5-8]. Albu-
minuria was estimated to contribute 75% of the risk of
all-cause natural death during a short longitudinal
period of observation [1]. Recently the authors reported
that albuminuria was still a remarkable predictor for
all-cause natural death over an average of 14 years
follow-up interval in an Aboriginal community [9]. Thus
albuminuria represents a potential target for intervention
[10]. A number of variables were measured in a cross-
sectional survey on a high-risk Australian Aboriginal
population. Thus this study aims to explore the asso-
ciations between demographic factors, anthropometric
index, blood pressure, lipid-protein measurements andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2369/14/176other biomarkers and albuminuria. The models will be
evaluated for albuminuria at or above the microalbumi-
nuria threshold, and at or above the “overt albuminuria”
threshold with the potential to distinguish associations
they have in common and those that differ.
Methods
Study population
Participants were recruited from an Australian Aboriginal
community living in a remote area in Northern Territory
of Australia between 1992 and 1998 as part of a screening
program for chronic disease. Participants aged 18 years
and over were included in the analysis.
Measurements of baseline characteristics
Urinary albumin concentrations were measured simultan-
eously by both nephelometric and high-performance li-
quid chromatography techniques on random urine
sample. When we examined over a Z-score continuum of
their values, they were identical in defining clinical profiles
and predicting deaths [11]. Thus the results here are based
on the concentration measured using Beckman immuno-
assay on a Dade Behring Prospect Analyser, with reagents
and calibrators supplied by Dade Behring Diagnostics
(Sydney, Australia). Urinary creatinine concentration was
measured using an alkaline picrate method (Olympus
AU800 Autoanalyzer; interassay CV 2%). Simple an-
thropometric indices, blood pressure, glucose, lipoprotein
profiles, C-reactive protein (CRP), uric acid, serum albu-
min, cystatin C, serum gamma glutammyl transferase
(GGT) and alanine amino transferase (ALT) were also
measured. The sex-specific cut points of ACR were ap-
plied to categorise participants as, normal (ACR < 17 mg/g
for men; <25 for women), microalbuminuria (ACR 17–
249 for men; 25–354 for women) and overt albuminuria
(ACR ≥ 250 for men; ≥355 for women) [12].
Diabetes refers to those known to be diabetic before
the baseline survey or who had fasting glucose ≥126 or
2-hr glucose ≥199.8 mg/dl or “random glucose” ≥199.8
mg/dl. Smoking and alcohol drinking were self-reported.
All participants were regrouped into quartiles by age.
Continuous variables that are not normal distributed
were logarithm-transferred prior to analysis.
Statistical analysis
Logistic regression modellings for ACR categories in-
cluding all potential predictors available in this study
were applied. All analyses were undertaken using Stata
11.1 (Stata Corp. Stata Statistical Software: Release 11.1,
College Station. TX: StatCorp LP, 2009).
The informed consent for the original population
screening program was obtained prior to the survey.
This study was approved by the Ethics Committee of the
Menzies School of Health Research and Territory HealthServices and The Behavioural and Social Science Ethical
Review Committee of the University of Queensland.
Results
Characteristics of participants
At the baseline survey, ACR was measured in a total of
755 participants aged 18 years and over, and 598 of them
with a complete set of risk factor measurements were in-
cluded in the analysis. Age ranged from 18 to 76 years,
with a mean of 34 years. The geometric mean, (95% CI)
ACR value was 32.6 mg/g (27.5-38.7).
Proportion of participants with normal ACR (using sex-
specific cut-off points) was 47.8% while microalbuminuria
and overt albuminuria were present in 40.8% and 19.2%,
respectively.
BMI, SBP, cholesterol, triglycerides, CRP, cystatin c,
serum GGT and diabetes prevalence increased with the
age while HDL and serum albumin were opposite
(Table 1). Uric acid and serum ALT were not associated
with age. The proportion of smokers was significantly
high in this community ranged from 67-78% (Table 1).
Logistic regression
In the logistic regression modelling, SBP, serum uric acid,
CRP and diabetes were significantly associated with albu-
minuria (Table 2) and it was marginally significant for GGT
(p = 0.054) while there was significantly inverse relationship
between serum albumin and albuminuria (Table 2). Table 3
shows that the independent correlates of microalbuminuria
were SBP, CRP, serum albumin (inverse association) and
uric acid (marginally significantly, p = 0.068) while the inde-
pendent predictors of overt albuminuria were total choles-
terol, SBP, uric acid, cystatin c, diabetes, serum albumin
and ALT (both were negative association).
Figures 1 and 2 shows the predicted amplification of
albuminuria and overt albuminuria produced by the sim-
ultaneous presence of risk factors identified as independ-
ent predictors in the final multivariate model. The
predictors were categorical variables derived from each
continuous variable using sex-specific median value as
the cut-off point. There were substantial rates of ele-
vated ACR (≥17 mg/g for men; ≥25 for women) with in-
creasing age even in the absence of other factors which
had independent correlations with ACR. However, the
probability of overt albuminuria with increasing age
alone was more modest.
Discussion
In this high risk Aboriginal population, SBP, serum albu-
min (inverse association), uric acid, CRP, diabetes were
significantly associated with albuminuria (p value for
GGT was 0.054).
SBP, serum albumin, CRP were significantly associated
with microalbuminuria (p value for uric acid was 0.068)
Table 1 Characteristics of participants by age quartile
Quartile 1 Quartile 2 Quartile 3 Quartile 4
(n = 150) (n = 151) (n = 149) (n = 148)
Age (years) (mean, SD) 21.6 (1.8) 27.7 (1.9) 35.8 (2.9) 50.8 (8.2)
BMI (kg/m2) (mean, SD) 21.4 (4.5) 23.6 (4.8) 24.5 (5.4) 24.5 (5.2)
SBP (mmHg) (mean, SD) 116.2 (15.7) 118.8 (15.1) 119.4 (16.7) 130.7 (21.8)
Cholesterol (mg/dL) (mean, SD) 4.12 (0.82) 4.69 (1.03) 4.86 (1.13) 4.99 (1.06)
HDL (mg/dL) (mean, SD) 1.14 (0.26) 1.14 (0.35) 1.12 (0.29) 1.06 (0.22)
Serum albumin (g/l) (mean, SD) 42.1 (4.8) 41.3 (5.7) 39.9 (5.1) 38.5 (4.6)
Uric acid (mg/l) (gmean, 95% CI) 0.34 (0.32–0.36) 0.36 (0.34–0.37) 0.35 (0.34–0.37) 0.35 (0.34–0.36)
Triglyceride (mg/dL) (gmean, 95% CI) 1.20 (1.13–1.28) 1.78 (1.63–1.94) 1.88 (1.70–2.08) 2.08 (1.91–2.25)
CRP (mg/l) (gmean, 95% CI) 3.84 (3.21–4.61) 3.97 (3.35–4.71) 5.74 (4.77–6.89) 6.61 (5.60–7.80)
Cystatin C (mg/l) (gmean,95% CI) 0.67 (0.66–0.69) 0.67 (0.65–0.70) 0.71 (0.68–0.74) 0.76 (0.73–0.80)
Serum ALT (IU/L) (gmean,95% CI) 24.0 (22.4–25.6) 26.7 (24.8–28.9) 23.2 (21.4–25.1) 19.4 (17.9–21.1)
Serum GGT (IU/L) (gmean, 95% CI) 26.9 (24.7–29.2) 36.2 (32.7–40.1) 37.7 (33.7–42.1) 38.0 (34.0–42.5)
Diabetes (%, 95% CI) 4.0 (0.8–7.1) 4.0 (0.8–7.1) 9.4 (4.7–14.1) 28.3 (21.0–35.7)
Smoking (%, 95% CI) 73.3 (66.1–80.5) 78.1 (71.5–84.8) 67.1 (59.5–74.7) 76.3 (69.4–83.2)
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ALT, cystatin C and diabetes were significantly associated
with overt albuminuria. The shared and the different risk
factors for these conditions, traditionally considered to be
stages of albuminuria over a continuum, suggest that
microalbuminuria and overt albuminuria might reflect dif-
ferent as well as shared phenomena. Different or inconsist-
ent associations of albuminuria with abdominal obesity
have been reported in some other studies [13-16] but no
significant evidence in this study. Macroalbuminuria was
independently associated with hypertension, diabetesTable 2 Logistic regression of any albuminuria (ACR ≥ 17
mg/g for men; ≥25 for women)
Variables Odds ratio 95% CI P
Age 1.15 0.94–1.40 0.181
BMI 0.99 0.95–1.04 0.767
Cholesterol 1.09 0.87–1.37 0.429
HDL 0.63 0.29–1.38 0.253
SBP 1.02 1.01–1.03 0.004
Serum albumin 0.91 0.87–0.95 <0.001
Serum uric acid* 3.16 1.31–7.61 0.010
ALT* 1.01 0.62–1.65 0.995
CRP* 1.29 1.07–1.57 0.009
Cystatin C* 1.69 0.66–4.30 0.275
Triglycerides* 1.47 0.93–2.30 0.103
GGT* 1.50 0.98–2.31 0.054
Diabetes 2.49 1.18–5.24 0.016
Smoking 1.05 0.68–1.64 0.853
*log–transformed.and abdominal obesity in Central Australian Aboriginal
communities [13].
A close link between high blood pressure and
microalbuminuria has been reported by others. In the
relationship, higher blood pressure might cause microal-
buminuria by increasing glomerular filtration pressure
and subsequent renal damage, [17] and adequate control
of SBP was associated with low risk for development of
microalbuminuria [18]. In addition, the magnitude of
urinary albumin excretion determines the severity of BP
elevation, [19,20] and there exist heritability and genetic
associations between increased urinary albumin excre-
tion and BP in some ethnic groups [21]. CRP, a member
of the class of acute phase reactants, is regarded as a
sensitive marker of inflammation and was reported as an
important contributor to albuminuria (but not an inde-
pendent predictor for overt albuminuria) in this study.
CRP levels are affected significantly by an individual’s
genetic makeup and life style [22,23]. People who smoke,
have elevated BP, who are overweight or have less phys-
ical activity, tend to have higher level of CRP [24,25].
CRP has been reported to be a novel cardiovascular risk
factor, [26] and we have reported that it is independently
associated with the development of diabetes in this Abo-
riginal cohort [27]. A significant association between
CRP level and microabuminuria has also been reported
in some other epidemiological studies [26,28-30]. The
relationship might indicate that chronic inflammation is
a potential mediator between microalbuminuria and car-
diovascular disease (CVD) [28].
A significant inverse association was found between
serum albumin and albuminuria, even after adjusting for
a number of confounding factors in this study. Albumin
Table 3 Logistic regression modellings for microalbuminuria and overt albuminuria
Microalbuminuria Overt albuminuria
Variables Odds ratio 95% CI P Odds ratio 95% CI P
Age 1.15 0.94–1.43 0.187 1.11 0.83–1.47 0.491
BMI 0.98 0.94–1.03 0.454 1.04 0.98–1.10 0.183
Cholesterol 0.99 0.78–1.27 0.963 1.49 1.11–1.99 0.009
HDL 0.71 0.31–1.62 0.418 0.51 0.15–1.73 0.281
SBP 1.02 1.0–1.03 0.016 1.02 1.00–1.03 0.020
Serum uric acid 2.42 0.94–6.24 0.068 3.66 1.11–12.0 0.029
Serum albumin 0.95 0.91–0.99 0.044 0.85 0.80–0.90 <0.001
ALT* 1.29 0.76–2.20 0.355 0.50 0.27–0.94 0.031
CRP* 1.33 1.08–1.64 0.007 1.05 0.80–1.38 0.713
Cystatin C* 0.58 0.16–2.06 0.390 8.20 2.68–25.1 <0.001
Triglycerides* 1.48 0.92–2.40 0.114 1.48 0.79–2.76 0.225
GGT* 1.33 0.84–2.11 0.202 1.50 0.88–2.58 0.136
Diabetes 1.88 0.83–4.25 0.133 2.41 1.20–4.87 0.014
Smoking 1.15 0.71–1.86 0.584 0.74 0.40–1.35 0.326
*log–transformed.
Notes: Microalbuminuria refers to ACR 17–249 mg/g for men and 25–354 for women; Overt albuminuria: ACR ≥ 250 for men and ≥355 for women.
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serum albumin may also indicate some conditions other
than liver dysfunction. Serum albumin levels are lowered
by infection and inflammation, and they decrease as a
consequence of acute phase inflammatory reactions, [31]
in which increased cytokines switch protein synthesis in
the liver from albumin to other phase proteins, and
serum albumin falls [32]. Serum albumin levels were also
inversely related to age in this study, and, ironically, have
been described as higher in smokers than non-smokers
[33,34]. Thus, further evaluation in longitudinal studies0.0
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Figure 1 Predicted amplification of albuminuria by multiple risk factois required to determine if the inverse relation between
serum albumin and albuminuria is causal.
Other reports describe that lower levels of pathologic
albuminuria are significantly associated with cigarette
smoking and heavy alcohol consumption [35]. However
there was no significant association between smoking
and albuminuria in our study. Serum GGT has long
been used as a liver function test and a marker of exces-
sive alcohol use; [36,37] about 35% of women and 87%
of men in this cohort were drinkers, with of men with
most males drinking to excess [38]. Associations+High uric acid
+High GGT
+Diabetes
+High CRP
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Figure 2 Predicted amplification of overt albuminuria by multiple risk factors.
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[33] and hypertension [38] have been reported. Our
findings support the observation that GGT might also
be a novel predictor of chronic kidney disease [39,40].
The possible mechanism of such associations is that oxi-
dative stress depletes glutathione stores which leads to a
compensatory increase in GGT, [41,42] or more free
radicals might contribute to high levels of GGT [43,44].
There is also evidence that high GGT in certain people
is genetically based [45,46]. As serum GGT is easy and
cheap to measure, it might have important practical im-
plications on predicting albuminuria and other chronic
diseases in Aboriginal communities.
Strengths of this study include the fact that over 80%
adult population in this remote Aboriginal community
participated. In addition, as Aboriginal people have sig-
nificantly higher prevalence of chronic kidney disease
(CKD), an easy implemented risk prediction model
based on routinely obtained laboratory test is important
[47]. In this study, all correlates of albuminuria were de-
rived from the available clinical information, and import-
ant metabolic markers such as Cystatin C, uric acid and
serum albumin were included in the data analysis. Both
the albumin and the CRP have helped shed light on the
possibly different associations depending on the level of
albuminuria. Third, strength is that we now know that
these relationships will apply whether ACR is measured
by immunoassay rather than HPLC, as we have proven
that both are identical in defining clinical profiles and
predicting deaths in this community [11].
There were also some limitations in this study. First,
the risk predictors in this study were derived from cross-
sectional data only, causal association might not exist orthe correlates might not be the same in future forecasting.
In fact, some correlates are probably markers of the CKD
and CVD risk state rather than causal. A 14–16 year longi-
tudinal study in this community is now under analysis and
one of reports revealed that albuminuria was still a signifi-
cant predictor of all-cause natural death after a 14-year
interval in this Aboriginal community. However more lon-
gitudinal outcomes would shed further light on this issue.
Second, with inclusion of new markers, the numbers went
down (from 755 down to 598). Those omitted were
slightly older (37 yrs vs. 33 yrs), with higher DBP level (78
mmHg vs. 74 mmHg) and higher prevalence of diabetes
(16% vs. 6%) than those included. It indicates that this
study may underestimate the strength of correlates to
ACR in this community. Third, random rather than 24-h
urine ACR value was used to define albuminuria in this
study. However, the spot ACR is a validated screening test
for microalbuminuria and has been used in this setting for
13 years, with widely published data [13]. Finally, findings
from a remote community in the Northern Territory of
Australia might not be generalizable to other populations.
However, most of the significant correlates in our studies
have been demonstrated in other settings [7,48-51].
Conclusions
This is the most detailed modeling of pathologic albu-
minuria in this setting to date. In this study, SBP, CRP,
lower serum albumin, uric acid, GGT and diabetes were
significantly associated with albuminuria in the Aborigi-
nal population. The somewhat variable association with
risk factors suggests that microalbuminuria and overt
albuminuria might reflect different as well as shared
phenomena.
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